Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation

Inclusion criteria

• Recipients, adults of the first living or deceased donor kidney transplant;
• Patients who agreed to participate in the study and signed the informed consent form

Exclusion criteria

• Receptors with a medical history of nephrotic syndrome or focal and segmental glomerulosclerosis confirmed as the etiology of end-stage renal disease;
• Receptors with poor understanding about chronic kidney disease and its treatment alternatives;
• Receptors with early history of non compliance to treatment with immunosuppressive drugs;
• Retransplantation;
• Multi-organ recipients;
• Recipients with BMI> 30 kg / m2;
• KDPI> 80%;
• Cold ischemia time greater than 24 hours;
• Receptors with a percentage of anti-HLA antibodies above 50%, either class I or Class II;
• Women of childbearing potential who do not undertake contraceptive methods (condoms or oral contraceptives).
• Patients receiving immunosuppressive therapy prior to transplantation, except low dose of prednisone;
• Patients with severe uncontrolled dyslipidemia;
• Patients who have a known contraindication for administration of any of the immunosuppressive drugs provided for in this study;